Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view

dc.contributor.authorCraig, Sonya
dc.contributor.authorPepin, Jean Louis
dc.contributor.authorRanderath, Winfried
dc.contributor.authorCaussé, Christian
dc.contributor.authorVerbraecken, Johan
dc.contributor.authorAsin, Jerryll
dc.contributor.authorBarbé Illa, Ferran
dc.contributor.authorBonsignore, Maria R.
dc.date.accessioned2022-11-26T18:39:58Z
dc.date.available2022-11-26T18:39:58Z
dc.date.issued2022
dc.description.abstractExcessive daytime sleepiness (EDS) is a major symptom of obstructive sleep apnoea (OSA), defined as the inability to stay awake during the day. Its clinical descriptors remain elusive, and the pathogenesis is complex, with disorders such as insufficient sleep and depression commonly associated. Subjective EDS can be evaluated using the Epworth Sleepiness Scale, in which the patient reports the probability of dozing in certain situations; however, its reliability has been challenged. Objective tests such as the multiple sleep latency test or the maintenance of wakefulness test are not commonly used in patients with OSA, since they require nocturnal polysomnography, daytime testing and are expensive. Drugs for EDS are available in the United States but were discontinued in Europe some time ago. For European respiratory physicians, treatment of EDS with medication is new and they may lack experience in pharmacological treatment of EDS, while novel wake-promoting drugs have been recently developed and approved for clinical use in OSA patients in the USA and Europe. This review will discuss 1) the potential prognostic significance of EDS in OSA patients at diagnosis, 2) the prevalence and predictors of residual EDS in treated OSA patients, and 3) the evolution of therapy for EDS specifically for Europe.ca_ES
dc.identifier.doihttps://doi.org/10.1183/16000617.0230-2021
dc.identifier.idgrec032561
dc.identifier.issn0905-9180
dc.identifier.urihttp://hdl.handle.net/10459.1/84367
dc.language.isoengca_ES
dc.publisherEuropean Respiratory Societyca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.1183/16000617.0230-2021ca_ES
dc.relation.ispartofEuropean Respiratory Review, 2022, vol. 31, núm. 164, art. 210230ca_ES
dc.rightscc-by-nc (c) Sonya Craig et. al., 2022ca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.otherSon--Pacientsca_ES
dc.subject.otherSíndromes d'apnea del sonca_ES
dc.titleInvestigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European viewca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
032561.pdf
Size:
450.34 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: